Tiziana Life Sciences (NASDAQ:TLSA) Trading Up 2.1%


Share on StockTwits

Tiziana Life Sciences PLC (NASDAQ:TLSA) shares were up 2.1% during mid-day trading on Tuesday . The stock traded as high as $2.95 and last traded at $2.92. Approximately 134,036 shares traded hands during trading, a decline of 87% from the average daily volume of 1,027,457 shares. The stock had previously closed at $2.86.

Several equities analysts have recently issued reports on TLSA shares. Zacks Investment Research downgraded shares of Tiziana Life Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, February 23rd. B. Riley started coverage on shares of Tiziana Life Sciences in a report on Tuesday, December 22nd. They set a “buy” rating and a $8.00 price objective on the stock.

The stock has a 50-day moving average of $3.05 and a 200 day moving average of $3.21. The stock has a market cap of $181.74 million, a PE ratio of -94.33 and a beta of 1.41.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. HighTower Advisors LLC boosted its position in Tiziana Life Sciences by 1.5% in the fourth quarter. HighTower Advisors LLC now owns 4,051,084 shares of the company’s stock valued at $8,183,000 after buying an additional 60,000 shares during the last quarter. Renaissance Technologies LLC boosted its position in Tiziana Life Sciences by 59.5% in the 4th quarter. Renaissance Technologies LLC now owns 358,348 shares of the company’s stock worth $724,000 after purchasing an additional 133,700 shares in the last quarter. Morgan Stanley boosted its position in Tiziana Life Sciences by 2,700.7% in the 3rd quarter. Morgan Stanley now owns 350,005 shares of the company’s stock worth $1,165,000 after purchasing an additional 337,508 shares in the last quarter. State Street Corp purchased a new stake in Tiziana Life Sciences in the 3rd quarter worth approximately $645,000. Finally, Orion Portfolio Solutions LLC boosted its position in Tiziana Life Sciences by 130.6% in the 4th quarter. Orion Portfolio Solutions LLC now owns 40,633 shares of the company’s stock worth $82,000 after purchasing an additional 23,013 shares in the last quarter.

About Tiziana Life Sciences (NASDAQ:TLSA)

Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.

See Also: Hedge Funds Explained

Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.